- Home
- CYTH vs MIRA Comparison
CYTH vs MIRA Comparison
Compare CYTH & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTH
- MIRA
- Stock Information
- Founded
- CYTH 1990
- MIRA 2020
- Country
- CYTH United States
- MIRA United States
- Employees
- CYTH N/A
- MIRA N/A
- Industry
- CYTH Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- CYTH Health Care
- MIRA Health Care
- Exchange
- CYTH Nasdaq
- MIRA Nasdaq
- Market Cap
- CYTH 20.4M
- MIRA 17.4M
- IPO Year
- CYTH N/A
- MIRA 2023
- Fundamental
- Price
- CYTH $0.63
- MIRA $1.06
- Analyst Decision
- CYTH Buy
- MIRA Strong Buy
- Analyst Count
- CYTH 3
- MIRA 2
- Target Price
- CYTH $0.95
- MIRA $14.00
- AVG Volume (30 Days)
- CYTH 43.6K
- MIRA 511.1K
- Earning Date
- CYTH 11-14-2024
- MIRA 11-12-2024
- Dividend Yield
- CYTH N/A
- MIRA N/A
- EPS Growth
- CYTH N/A
- MIRA N/A
- EPS
- CYTH N/A
- MIRA N/A
- Revenue
- CYTH $870,725.00
- MIRA N/A
- Revenue This Year
- CYTH N/A
- MIRA N/A
- Revenue Next Year
- CYTH $24.49
- MIRA N/A
- P/E Ratio
- CYTH N/A
- MIRA N/A
- Revenue Growth
- CYTH N/A
- MIRA N/A
- 52 Week Low
- CYTH $0.57
- MIRA $0.51
- 52 Week High
- CYTH $2.12
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- CYTH 46.82
- MIRA 37.68
- Support Level
- CYTH $0.60
- MIRA $0.98
- Resistance Level
- CYTH $0.69
- MIRA $1.16
- Average True Range (ATR)
- CYTH 0.04
- MIRA 0.09
- MACD
- CYTH 0.00
- MIRA -0.01
- Stochastic Oscillator
- CYTH 50.00
- MIRA 24.26
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.